The Morphological Evaluation of Walker 256 Tumors after Antiangiogenetic Therapy in Rats by IRIMIE, Alexandra et al.
The Morphological Evaluation of Walker 256 
Tumors after Antiangiogenetic Therapy in Rats
Alexandra IRIMIE1*, Attila Tamas SZORA2, Mihai SOCACIU2, Alexandru Flaviu TĂBĂRAN1, Raluca VIDRI-
GHINESCU1, Cornel CĂTOI1
1Department of  Pathology, University of Agricultural Sciences and Veterinary Medicine, Cluj Napoca, 
Romania
2Ultrasonography Department, 3rd Medical Clinic,“Iuliu Haţieganu” University of Medicine and Phar-
macy, Cluj Napoca, Romania
*Corresponding author, e-mail: alexandra.irimie2010@gmail.com
Bulletin UASVM Veterinary Medicine 71(2) / 2014, 
Print ISSN 1843-5270; Electronic ISSN 1843-5378
DOI:10.15835/buasvmcn-vm: 10558
Abstract
Sunitinib Malate is a multi-targeted receptor tyrosine kinase inhibitor, including the vascular endothelial growth 
factor receptors, and is used for treatment of pancreatic neuroendocrine, renal cell carcinoma and gastrointestinal 
stromal tumors. The formation of new blood vessels (angiogenesis) may consequently lead to the development 
of metastases and so the aim of this study was to evaluate the microvessel density (MVD) after sunitinib malate 
treatment. In this study 11 albino Wistar rats were inoculated subcutaneously with Walker 256 tumor (breast 
carcinoma cells) and after 5 weeks, 5 rats were administered sunitinib malate at a dosage of 40 mg/kg every 3 
days for 2 weeks. After another 4 weeks the tumors were removed and morphologically evaluated (weighted, 
measured). The MVD determined and quantiϐied by calculating the average between 3 random ϐields. In the 
tumoral stroma we calculated also the vascular area. The immunohistochemical analysis of the neovascularization 
was performed using an anti-rat antibody against CD34. The difference between tumor weights were statistical 
signiϐicant (p<0.05) (3.746 ± 1.633; 1.019 ± 0.812) but the tumor sizes and most importantly MVD between the 
control group and the experimental group were not statistical signiϐicant (p>0.05) (32.55 ± 18.83; 18.6 ± 4.734). 
As a conclusion, the rats treated with Sunitinib malate did not show a lower microvessel density comparative to the 
untreated ones. The number of rats used in this research was too small and further studies are needed.
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INTRODUCTION
Angiogenesis deϐines the formation of new 
blood vessels. All tissues require a continuous 
supply of oxygen including the tumoral tissue. 
Oxygen is conducted to these tissues by blood 
capillaries: more capillaries can increase tissue 
oxygenation and thus enhance energy production; 
fewer capillaries can lead to hypoxia and even 
anoxia in the tissues (Adair and Montani, 2010). 
Also the formation of new blood vessels may lead 
to the development of metastases with the in-going 
of the malignant cells into the circulation. Thus the 
antiangiogenetic therapies are designed to reduce 
and control the growth of these new blood vessels 
and to induce the death of the tumor cells. The 
antiangiogenetic therapies are a possible cancer 
treatment.
Sunitinib Malate is a multi-targeted receptor 
tyrosine kinase inhibitor, including the vascular 
endothelial growth factor receptors, and is used 
for treatment of pancreatic neuroendocrine, 
renal cell carcinoma and gastrointestinal stromal 
tumors (FDA Approval summary). 
For over 10 years, microvessel density (MVD) 
was used as a surrogate marker of tumoral angio-
genesis and is the most commonly used techni-
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que to quantify intratumoral angiogenesis 
in breast cancer. It was ϐirst developed by 
Weidner et al. in 1991 and uses panendothelial 
immunohistochemical staining of blood micro-
vessels (Factor VIII antigen, CD31, PECAM-1, or 
CD34, etc.) (Uzzan et al., 2004). 
The aim of this study was to evaluate the 
microvessel density (MVD) after sunitinib malate 
treatment.  
MATERIALS AND METHODS
In this study 11 albino Wistar rats were 
inoculated subcutaneously with Walker 256 
tumor (breast carcinoma cells) and after 5 weeks, 
5 rats were administered sunitinib malate at 
a dosage of 40 mg/kg every 3 days for 2 weeks. 
After another 4 weeks the tumors were removed, 
photographed and morphologically evaluated 
(weighted, measured).    
Histology 
The samples were ϐixed immediately after 
excision in 10% neutral buffered formalin for 
24 hours and embedded in parafϐin wax. Serial 
sections were cut at 4 μm from each block and 
stained with hematoxylin and eosin (H&E). 
Immunohistochemistry
The immunohistochemical study was realised 
by using anti-CD34 antibodies (diluatia 1:10, R&D 
Systems, Minneapolis, USA).  Serial sections were 
cut at 4 μm from each block and mounted on poly-L 
lysine coated slides. The immunohistochemical 
protocol was performed using the Leica Bond Max 
automatic system.
Microvessel Density (MVD)
The microvessel density was determined 
using light microscopy. The microscope used in 
this study was an Olympus BX41 microscope with 
an Olympus UC30  photo camera and an Olympus 
Stream Basic software.  Using Weidner’s approach 
(1991), 3 random ϐields were established by using 
a 10X objective lens (100X magniϐication), where 
the most capillaries (“hot spot”) can be observed. 
The capillaries in both the tumor stroma and the 
tumor capsule were counted using a 20X objective 
lens (200X magniϐication). After the capillaries 
were counted, the average was calculated between 
these ϐields. At the same time the area of the 
large and medium large vessels was calculated 
in percentage (vascular area reported to the total 
area of the ϐield). The total area of the ϐield was
377956.98 μm2.
Tab. 1. Tumor weights 
Weight (g) – untreated 
group   








Fig. 1. The Untreated Group (a) H&E stain. (b) Immunohistochemical staining with antibody against CD34. 
Positive capillary endothelial cells indicated by black arrows. Note the cytoplasmatic membranes of the tumor 
cells also marked.  Magniϐication at 200X.  
a b
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Statistics: Independent group t–tests were 
used to compare two groups in regard to the 
categorical data, by using Microsoft Excel.  
RESULTS AND DISCUSSIONS 
After the tumors were weighted there could 
be seen a signiϐicant difference between the 
experimental group and the untreated group 
(table 1). 
The difference between tumor weights were 
statistical signiϐicant (p<0.05) (3.746 ± 1.633; 
1.019 ± 0.812), but the tumor sizes and volumes 
were not statistical signiϐicant (p>0.05).  
The immunohistochemical analysis of the 
neovascularization was performed using an 
anti-rat antibody against CD34 and the positive 
endothelial cells were marked brown. 
As can be seen in both ϐigures the MVD has 
not been reduced in the experimental group. MVD 
between the control group and the experimental 
group were not statistical signiϐicant (p>0.05) 
(32.55 ± 18.83; 18.6 ± 4.734). 
In his ϐirst study Weidner et al. (1991) used 
an antibody against factor VIII-related antigen, 
staining mainly mature vessels and cross-reacting 
with lymphatic endothelium. After that, recent 
studies used antibodies directed against platelet 
endothelial cell adhesion molecule: CD31 or CD34. 
Both antibodies have the same characteristics with 
the difference that CD31 can react with ϐibrobasts 
and plasma cells. With that consideration we have 
chosen the CD34 antibody. 
Olga Potapova et al. (2006) studied the 
contribution of individual targets to the antitumor 
Tab. 3. The microvessel density (MVD) and vascu-
lar area in the experimental group
MVD Vascular Area (%)
19.66 (S 4 + C 55) 0.02
24.33 (S 9 + C 64) 1.28
20 (S 48 + C 12) 3.53
17.66 ( S 28 + C 25) 1.4
11.33 ( S 19 + C 15) 0.36
S – stroma ; C – capsule   
Tab. 2. The microvessel density (MVD) and vas-
cular area in the untreated group
MVD Vascular Area (%)
32.33 (S 16+ C 81) 3.44
32 (S 25 + C 71) 3.17
19 (S 7+ C 50) 1.04
24.33 (S 37 + C 36) 2.33
18.66 (S 37 +C 19) 6.35
69 (S 70 + C 137) 4.56
S – stroma ; C – capsule   
Fig. 2. The Experimental Group. (a) H&E stain (b) Immunohistochemical staining with antibody against CD34. 
Positive capillary endothelial cells indicated by black arrows.  
a b
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efϐicacy of the sunitinib malate and reached the 
conclusion that in vivo preclinical mechanism of 
action of the class III/V RTK inhibitor SU11248 is 
a combination of direct antitumor cell effects and 
antiangiogenic inhibition of tumor neovasculature. 
In the study performed by Mousseau et al. 
(2012) they stated that ,orally administered, the 
combination of sunitinib malate and ϐingolimod 
greatly decreased rat breast tumor growth in a 
syngeneic cancer model (Walker 256). They stated 
also that these drugs may provide an effective 
means of reducing tumor angiogenesis, and may 
improve the delivery of other chemotherapies. 
In this study sunitinib malate did not have the 
desired effect by reducing the tumor volumes and 
reducing the MVD. 
CONCLUSIONS
As a conclusion, the rats treated with Sunitinib 
malate did not show a lower microvessel density 
comparative to the untreated ones. The number 
of rats used in this research was too small and 
further studies are needed.  
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